Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the <scp>LYSA</scp> group
Developing new therapeutic regimens for relapsed/refractory (R/R) B non-Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti-CD20-containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA-promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL, n = 58), diffuse large B-cell lymphoma (DLBCL, n = 58) and marginal zone lymphoma (MZL, n = 20). The primary end-point for FL and DLBCL was not met: ATE, OBI, and VEN resulted in an overall response rate (ORR) at the end of induction (EOI) of 53.6% for FL (cohort 1) and 23.6% for DLBCL (cohort 2) when a minimum of 70% and 48% was expected respectively. The median progression-free survival was 11.0 and 2.7 months in cohorts 1 and 2 respectively. In cohort 3 (MZL), the ORR at the EOI was evaluated at 66.7%. The most frequent adverse events (AEs) were cytopenias. We also observed 7.4% of autoimmune AE imputable to the combination. In this phase II study, ATE, OBI and VEN demonstrated moderate efficacy and a manageable toxicity profile when used as induction and maintenance therapy.
Authors
- Hervé Tilly (ORCID: https://orcid.org/0000-0001-7022-5246)
- Emmanuelle Nicolas‐Virelizier (ORCID: https://orcid.org/0000-0002-8450-4593)
- Loïc Ysebaert (ORCID: https://orcid.org/0000-0003-4102-7261)
- Steven Le Gouill (ORCID: https://orcid.org/0000-0001-9840-2128)
- Morgane Cheminant (ORCID: https://orcid.org/0000-0002-2070-9581)
- Luc‐Matthieu Fornecker (ORCID: https://orcid.org/0000-0002-1866-971X)
- Corinne Haïoun (ORCID: https://orcid.org/0000-0003-0095-5379)
- Guillaume Cartron (ORCID: https://orcid.org/0000-0003-0659-9635)
- Charles Herbaux (ORCID: https://orcid.org/0000-0003-4910-476X)
- Franck Morschhauser (ORCID: https://orcid.org/0000-0002-3714-9824)
- Emmanuel Bachy (ORCID: https://orcid.org/0000-0003-2694-7510)
- Olivier Casasnovas (ORCID: https://orcid.org/0000-0002-1156-8983)
- Gandhi Laurent Damaj (ORCID: https://orcid.org/0000-0002-4689-3882)
- Catherine Thieblemont
- Rémy Gressin (ORCID: https://orcid.org/0000-0002-9188-3501)
- Emmanuel Gyan (ORCID: https://orcid.org/0000-0002-7651-9189)
- Nadine Morineau (ORCID: https://orcid.org/0000-0002-1190-8503)
- Stéphanie Guidez
- Nicolas Daguindau
- Roch Houot
- Pierre Feugier
- Réda Bouabdallah
Institutions
- Université de Tours (FR)
- Hôpital Necker-Enfants Malades (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Institut de Cancérologie Strasbourg (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Léon Bérard (FR)
- Roche (France) (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Hôpital Lyon Sud (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Annecy Genevois (FR)
- Hôpital Saint-Louis (FR)
- Centre Hospitalier Départemental Vendée (FR)
- Institut Paoli-Calmettes (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Institut de Génétique Humaine (FR)
- Université de Rennes (FR)
- Institut Curie (FR)
- Université Grenoble Alpes (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1111/bjh.20109
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Roche